Webcast / Audiocast

0 Comments

31 March 2017

Commissioning through Evaluation

Dr Jim McLenachan

Leeds

Previous | Next

Summary

Dr McLenachan discusses the challenges involving getting treatments approved for prescribing and the changes to the commissioning stucture, including the abolition of Specialist Commissioning Groups and introduction of the National Specialised Commissioning Group.

Specifically, he touches upon PFO closure, Mitraclip and LAA occluder device implantation in those at high risk of bleeding.

Summary

Dr McLenachan discusses the challenges involving getting treatments approved for prescribing and the changes to the commissioning stucture, including the abolition of Specialist Commissioning Groups and introduction of the National Specialised Commissioning Group.

Specifically, he touches upon PFO closure, Mitraclip and LAA occluder device implantation in those at high risk of bleeding.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In